Morgan Stanley raised the firm’s price target on Eli Lilly (LLY) to $1,327 from $1,313 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- LifeMD now offering Foundayo from Eli Lilly
- Amazon Offers Same-Day Delivery of Eli Lilly’s (LLY) Weight-Loss Pill
- Morning News Wrap-Up 4/9/26: Today’s Biggest Stock Market Stories!
- XLV, VHT, IXJ: Invest in the Healthcare Sector with Exchange-Traded Funds
- Amazon Pharmacy to offer Eli Lilly’s Foundayo via same-day delivery